2023
DOI: 10.1002/cam4.6699
|View full text |Cite
|
Sign up to set email alerts
|

Improved efficiency of daratumumab treatment of multiple myeloma adopting the subcutaneous route: A micro‐costing analysis in three Italian hematology centers

Lorenzo Pradelli,
Massimo Massaia,
Elisabetta Todisco
et al.

Abstract: BackgroundDaratumumab is a humanized monoclonal antibody approved for the treatment of adult patients with newly diagnosed or relapsed/refractory multiple myeloma (RRMM). Subcutaneous (SC) formulation proved to be non‐inferior in comparison with intravenous (IV) administration route. This study aimed at assessing the economic and time impact associated with the use of SC versus IV daratumumab in patients with RRMM from the perspective of the hematology center.MethodsThis was a 5‐month multicenter time‐and‐moti… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
references
References 31 publications
0
0
0
Order By: Relevance